Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVXLNASDAQ:LUNANASDAQ:PIRSOTCMKTS:SPHRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$10.72+1.4%$8.58$4.00▼$14.44$915.17M0.721.19 million shs800,367 shsLUNALuna Innovations$0.95+5.0%$0.60$0.22▼$3.39$32.09M1.88193,759 shs11,220 shsPIRSPieris Pharmaceuticals$13.60$15.17$6.20▼$18.68$17.95M0.6185,715 shs51,728 shsSPHRYStarpharma$0.64+8.9%$0.58$0.47▼$0.80$26.73M0.76122 shs500 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences+1.42%+12.02%+36.73%+30.89%+160.19%LUNALuna Innovations+5.00%+12.50%+26.00%+89.38%-69.12%PIRSPieris Pharmaceuticals0.00%0.00%0.00%0.00%+56.68%SPHRYStarpharma+8.88%+11.28%+13.85%+8.32%+1.42%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVXLAnavex Life Sciences3.6325 of 5 stars3.70.00.04.71.40.80.6LUNALuna Innovations0.2826 of 5 stars0.01.00.00.02.51.70.0PIRSPieris PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASPHRYStarpharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVXLAnavex Life Sciences 3.33Buy$44.00310.45% UpsideLUNALuna Innovations 0.00N/AN/AN/APIRSPieris Pharmaceuticals 0.00N/AN/AN/ASPHRYStarpharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest LUNA, PIRS, AVXL, and SPHRY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/7/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.004/7/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVXLAnavex Life SciencesN/AN/AN/AN/A$1.42 per shareN/ALUNALuna Innovations$116.61M0.28$0.31 per share3.03N/A∞PIRSPieris Pharmaceuticals$42.81M0.42N/AN/A$21.66 per share0.63SPHRYStarpharma$6.40M4.18N/AN/A$0.45 per share1.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVXLAnavex Life Sciences-$43M-$0.55N/AN/AN/AN/A-40.93%-36.38%8/5/2025 (Estimated)LUNALuna Innovations$9.28MN/A0.00∞N/AN/AN/AN/AN/APIRSPieris Pharmaceuticals-$24.54M-$12.10N/A∞N/A-39.71%-80.93%-59.55%N/ASPHRYStarpharma-$5.36MN/A0.00∞N/AN/AN/AN/A8/20/2025 (Estimated)Latest LUNA, PIRS, AVXL, and SPHRY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q2 2025AVXLAnavex Life Sciences-$0.16-$0.13+$0.03-$0.13N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVXLAnavex Life SciencesN/AN/AN/AN/AN/ALUNALuna InnovationsN/AN/AN/AN/AN/APIRSPieris PharmaceuticalsN/AN/AN/AN/AN/ASPHRYStarpharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVXLAnavex Life SciencesN/A6.746.74LUNALuna InnovationsN/AN/AN/APIRSPieris PharmaceuticalsN/A4.824.82SPHRYStarpharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVXLAnavex Life Sciences31.55%LUNALuna Innovations87.46%PIRSPieris Pharmaceuticals40.11%SPHRYStarpharmaN/AInsider OwnershipCompanyInsider OwnershipAVXLAnavex Life Sciences11.40%LUNALuna Innovations7.60%PIRSPieris Pharmaceuticals6.39%SPHRYStarpharmaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVXLAnavex Life Sciences4085.37 million75.64 millionOptionableLUNALuna Innovations39033.96 million31.38 millionOptionablePIRSPieris Pharmaceuticals1401.32 million1.24 millionOptionableSPHRYStarpharma4541.82 millionN/ANot OptionableLUNA, PIRS, AVXL, and SPHRY HeadlinesRecent News About These CompaniesSPHRY Starpharma Holdings LimitedJune 19, 2025 | seekingalpha.comChange in Substantial Holder’s Voting Power at Starpharma HoldingsJune 3, 2025 | tipranks.comPleasing Signs As A Number Of Insiders Buy Starpharma Holdings StockMay 5, 2025 | uk.finance.yahoo.comStarpharma Advances Strategic Initiatives and Expands Market PresenceApril 29, 2025 | tipranks.comIs Starpharma Holdings (ASX:SPL) In A Good Position To Deliver On Growth Plans?March 25, 2025 | finance.yahoo.comRobmar Investments Acquires Substantial Stake in Starpharma HoldingsMarch 17, 2025 | tipranks.comStarpharma Highlights DEP® Dendrimer Platform at PepTalk ConferenceJanuary 15, 2025 | tipranks.comAstodrimer by Starpharma for Coronavirus Disease 2019 (COVID-19): Likelihood of ApprovalDecember 30, 2024 | pharmaceutical-technology.comPStarpharma CEO Receives Major Performance Rights IssuanceDecember 12, 2024 | markets.businessinsider.comStarpharma Issues Unquoted Securities to Boost Employee IncentivesDecember 12, 2024 | markets.businessinsider.comStarpharma Holdings Reports Successful AGM ResultsNovember 29, 2024 | tipranks.comStarpharma Holdings Schedules Reconvened AGM for Key VoteNovember 26, 2024 | tipranks.comStarpharma AGM Results Highlight Voting ChallengesNovember 26, 2024 | tipranks.comStarpharma Holdings Highlights Strategic Advances in 2024November 25, 2024 | tipranks.comStarpharma Highlights Dendrimer Technology at Healthcare ConferenceNovember 18, 2024 | markets.businessinsider.comStarpharma Showcases Dendrimer Innovations at Microcap ConferenceOctober 29, 2024 | markets.businessinsider.comMedicxi, Starpharma create Petalion with $25M roundApril 9, 2024 | bioworld.comBMedicxi and Starpharma to develop dendrimer-based cancer treatmentsApril 8, 2024 | pharmaceutical-technology.comPStarpharma Holdings Ltd. ADRMarch 14, 2024 | wsj.comNews - StarpharmaFebruary 20, 2024 | thepharmaletter.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLUNA, PIRS, AVXL, and SPHRY Company DescriptionsAnavex Life Sciences NASDAQ:AVXL$10.72 +0.15 (+1.42%) Closing price 07/3/2025 03:48 PM EasternExtended Trading$10.70 -0.02 (-0.19%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Luna Innovations NASDAQ:LUNA$0.94 +0.05 (+5.00%) As of 07/3/2025 10:44 AM EasternLuna Innovations Incorporated provides fiber optic test, measurement, and control products worldwide. The company offers test and measurement equipment for fiber optic components and sub-assemblies; polarization control products, including components, modules, and instruments to measure, manage, and control polarization and group delay in fiber optic networks; tunable lasers; and single frequency lasers. It also provides ODiSI sensing solution, which provides distributed strain and temperature measurements; distributed temperature sensing system; hyperion sensing products; Terahertz Sensing Systems that provide precise single and multi-layer thickness, density, basis weight, and caliper thickness measurements; and distributed acoustic sensing products. The company primarily markets its fiber optic test, measurement, and control products to telecommunications companies, defense agencies, government system integrators, researchers, original equipment manufacturers, distributors, testing labs, and strategic partners directly, as well as through manufacturer representative organizations, partner and distribution channels, technical sales engineers, value added resellers, and independent sales representatives. Luna Innovations Incorporated was incorporated in 1990 and is headquartered in Roanoke, Virginia.Pieris Pharmaceuticals NASDAQ:PIRSPieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.Starpharma OTCMKTS:SPHRY$0.64 +0.05 (+8.88%) As of 07/3/2025 12:52 PM EasternStarpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
